Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$5.02 USD
+0.14 (2.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PBYI 5.02 +0.14(2.87%)
Will PBYI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PBYI
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
Other News for PBYI
PBYI Crosses Above Average Analyst Target
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI Crosses Above Average Analyst Target